Xeris Pharmaceuticals has won approval in Europe for Ogluo (glucagon), an injectable treatment for severe hypoglycemia in adults, teenagers and children over two years old.

The approval was supported by a phase 3 study in 132 adults with type 1 diabetes, in which Ogluo showed comparable efficacy to Novo Nordisk’s glucagon injection.

Xeris plans to launch the drug in Europe this year in collaboration with a partner, according to Paul R. Edick, the company’s CEO and chairman.